(Q47427740)

16 January 2018

title

Effects of exendin-4 alone and with peptide YY(3-36) on food intake and body weight in diet-induced obese rats (English)

1 reference

16 January 2018

0 references

3

1 reference

16 January 2018

author name string

Roger D Reidelberger

1

1 reference

16 January 2018

Alvin C Haver

2

1 reference

16 January 2018

Krista L Anders

4

1 reference

16 January 2018

Sharalyn M Steenson

5

1 reference

16 January 2018

publication date

17 June 2010

1 reference

16 January 2018

published in

Obesity

1 reference

16 January 2018

volume

19

1 reference

16 January 2018

issue

1

1 reference

16 January 2018

page(s)

121-127

1 reference

16 January 2018

Effects of different intermittent peptide YY (3-36) dosing strategies on food intake, body weight, and adiposity in diet-induced obese rats

cites work

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.136

Intermittent intraperitoneal infusion of peptide YY(3-36) reduces daily food intake and adiposity in obese rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.136

Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.136

Prospective study of gut hormone and metabolic changes after adjustable gastric banding and Roux-en-Y gastric bypass

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.136

Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.136

Methods and protocols of modern solid phase Peptide synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.136

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.136

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.136

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.136

Antiobesity action of peripheral exenatide (exendin-4) in rodents: effects on food intake, body weight, metabolic status and side-effect measures

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.136

Peripheral exendin-4 and peptide YY(3-36) synergistically reduce food intake through different mechanisms in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.136

Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.136

Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.136

The GLP-1 agonist exendin-4 reduces food intake in nonhuman primates through changes in meal size.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.136

Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.136

Vagal sparing surgical technique but not stoma size affects body weight loss in rodent model of gastric bypass

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.136

Meal-induced hormone responses in a rat model of Roux-en-Y gastric bypass surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.136

PYY(3-36) induces Fos in the arcuate nucleus and in both catecholaminergic and non-catecholaminergic neurons in the nucleus tractus solitarius of rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.136

Combination therapy with amylin and peptide YY[3-36] in obese rodents: anorexigenic synergy and weight loss additivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.136

Antiobesity effects of the beta-cell hormone amylin in combination with phentermine or sibutramine in diet-induced obese rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.136

Interaction of leptin and amylin in the long-term maintenance of weight loss in diet-induced obese rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.136

Amylin-mediated restoration of leptin responsiveness in diet-induced obesity: magnitude and mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.136

Central exendin-4 infusion reduces body weight without altering plasma leptin in (fa/fa) Zucker rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.136

The function of leptin in nutrition, weight, and physiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.136

Causes and problems of nonresponse or poor response to drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.136

Effects of intermittent intraperitoneal infusion of salmon calcitonin on food intake and adiposity in obese rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.136

Daily, intermittent intravenous infusion of peptide YY(3-36) reduces daily food intake and adiposity in rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.136

Anthropometrical parameters and markers of obesity in rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.136

Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.136

Comparing rat's to human's age: how old is my rat in people years?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.136

Changes in GI hormones and their effect on gastric emptying and transit times after Roux-en-Y gastric bypass in rat model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.136

Is parental control over children's eating associated with childhood obesity? Results from a population-based sample of third graders

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.136

Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.136

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/OBY.2010.136

1 reference

16 January 2018

1 reference

16 January 2018